Rigel Pharmaceuticals (RIGL) Projected to Post Earnings on Tuesday

Rigel Pharmaceuticals (NASDAQ:RIGL) will likely be announcing its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect the company to announce earnings of $0.7950 per share and revenue of $62.3960 million for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

Rigel Pharmaceuticals (NASDAQ:RIGL) last issued its earnings results on Tuesday, March 3rd. The biotechnology company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.33 by ($0.19). Rigel Pharmaceuticals had a net margin of 124.72% and a return on equity of 79.84%. The firm had revenue of $69.80 million during the quarter, compared to analysts’ expectations of $68.70 million. On average, analysts expect Rigel Pharmaceuticals to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Rigel Pharmaceuticals Stock Performance

RIGL opened at $29.40 on Monday. Rigel Pharmaceuticals has a 12-month low of $16.88 and a 12-month high of $52.24. The company has a current ratio of 2.42, a quick ratio of 2.30 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $543.31 million, a PE ratio of 1.55 and a beta of 1.21. The firm has a 50 day moving average of $29.53 and a two-hundred day moving average of $35.57.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on RIGL shares. Citigroup reiterated a “buy” rating on shares of Rigel Pharmaceuticals in a research note on Wednesday, January 14th. Weiss Ratings restated a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a research report on Tuesday, April 21st. Zacks Research raised shares of Rigel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 18th. Finally, Wall Street Zen downgraded Rigel Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $45.67.

Insider Transactions at Rigel Pharmaceuticals

In related news, Director Walter H. Moos sold 4,000 shares of Rigel Pharmaceuticals stock in a transaction on Friday, February 20th. The shares were sold at an average price of $36.36, for a total value of $145,440.00. Following the sale, the director owned 12,722 shares of the company’s stock, valued at approximately $462,571.92. This trade represents a 23.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.47% of the company’s stock.

Institutional Investors Weigh In On Rigel Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Rigel Pharmaceuticals by 400.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,275 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 1,020 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Rigel Pharmaceuticals in the 3rd quarter valued at about $62,000. Wexford Capital LP purchased a new position in Rigel Pharmaceuticals in the third quarter worth approximately $66,000. Legal & General Group Plc grew its holdings in shares of Rigel Pharmaceuticals by 130.7% during the 2nd quarter. Legal & General Group Plc now owns 4,310 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 2,442 shares during the period. Finally, Truvestments Capital LLC boosted its stake in Rigel Pharmaceuticals by 120.3% during the fourth quarter. Truvestments Capital LLC now owns 2,207 shares of the biotechnology company’s stock worth $95,000 after buying an additional 1,205 shares during the period. 66.23% of the stock is currently owned by institutional investors and hedge funds.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).